Abraxane vs. Taxotere: Abraxis Prepares To Go Head-To-Head In Phase III Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Study comparing Abraxane to Sanofi’s Taxotere for first-line breast cancer will start in second half, along with lung cancer and melanoma studies.
You may also be interested in...
Benefits Of Avandia, Actos Outweigh Risks – EMEA
EMEA panel recommends additional warnings for rosiglitazone products, but gives positive opinion on continued marketing.
Benefits Of Avandia, Actos Outweigh Risks – EMEA
EMEA panel recommends additional warnings for rosiglitazone products, but gives positive opinion on continued marketing.
Abraxis Licenses Rights To Biosimilar From Indian Firm Biocon
Biocon will manufacture biogeneric of Amgen’s Neupogen for Abraxis, the firm tells “The Pink Sheet” DAILY.